Your browser doesn't support javascript.
loading
Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.
Park, Keunchil; Özgüroglu, Mustafa; Vansteenkiste, Johan; Spigel, David; Yang, James C-H; Bajars, Marcis; Ruisi, Mary; Manitz, Juliane; Barlesi, Fabrice.
Afiliação
  • Park K; Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: kpark@skku.edu.
  • Özgüroglu M; Department of Internal Medicine, Division of Medical Oncology, Cerrahpasa Medical Faculty, Istanbul University Cerrahpasa, Istanbul, Turkey. Electronic address: ozguroglu@gmail.com.
  • Vansteenkiste J; Department of Respiratory Oncology, University Hospital KU Leuven, Leuven, Belgium. Electronic address: johan.vansteenkiste@uzleuven.be.
  • Spigel D; Sarah Cannon Research Institute, Nashville, TN, USA. Electronic address: David.Spigel@sarahcannon.com.
  • Yang JC; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. Electronic address: chihyang@ntu.edu.tw.
  • Bajars M; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA; an affiliate of Merck KGaA, Darmstadt, Germany. Electronic address: marcis.bajars@emdserono.com.
  • Ruisi M; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA; an affiliate of Merck KGaA, Darmstadt, Germany. Electronic address: mary.ruisi@emdserono.com.
  • Manitz J; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA; an affiliate of Merck KGaA, Darmstadt, Germany. Electronic address: juliane.manitz@emdserono.com.
  • Barlesi F; Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France; Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: fabrice.barlesi@gustaveroussy.fr.
Lung Cancer ; 154: 92-98, 2021 04.
Article em En | MEDLINE | ID: mdl-33636453

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Checkpoint Imunológico / Neoplasias Pulmonares Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Checkpoint Imunológico / Neoplasias Pulmonares Idioma: En Ano de publicação: 2021 Tipo de documento: Article